Back to top
more

IntraCellular Therapies (ITCI)

(Delayed Data from NSDQ)

$70.16 USD

70.16
1,151,557

-1.77 (-2.46%)

Updated Feb 23, 2024 04:00 PM ET

After-Market: $70.19 +0.03 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.18%
2Buy17.85%
3Hold9.34%
4Sell5.12%
5Strong Sell2.62%
S&P50010.88%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Balance Sheet

Research for ITCI

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for IntraCellular Therapies Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents -99,999 594 414 659 224
Receivables NA 75 20 11 0
Notes Receivable NA 0 0 0 0
Inventories NA 24 8 7 0
Other Current Assets NA 45 25 14 6
Total Current Assets NA 738 467 691 230
Net Property & Equipment NA 2 2 2 2
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 0 0 0 0
Total Assets NA 755 490 717 251
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable NA 0 0 0 0
Accounts Payable NA 10 9 6 7
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 68 38 26 26
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 83 53 37 36
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 99 72 60 56
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 2,138 1,639 1,593 905
Retained Earnings NA -1,477 -1,221 -937 -710
Other Equity NA -4 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 656 418 657 195
Total Liabilities & Shareholder's Equity NA 755 490 717 251
Total Common Equity 0 656 418 657 195
Shares Outstanding 96.20 94.70 81.40 80.10 55.40
Book Value Per Share 0.00 6.93 5.13 8.20 3.52

Fiscal Year End for IntraCellular Therapies Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022
Assets          
Cash & Equivalents -99,999 495 515 540 594
Receivables NA 103 96 82 75
Notes Receivable NA 0 0 0 0
Inventories NA 43 42 28 24
Other Current Assets NA 62 46 56 45
Total Current Assets NA 702 698 706 738
Net Property & Equipment NA 2 2 2 2
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 0 0 0 0
Total Assets NA 718 714 722 755
Liabilities & Shareholders Equity 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022
Notes Payable NA 0 0 0 0
Accounts Payable NA 11 8 8 10
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 89 81 68 68
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 103 92 80 83
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 117 107 95 99
Shareholders Equity 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 2,191 2,174 2,152 2,138
Retained Earnings NA -1,589 -1,564 -1,522 -1,477
Other Equity NA -1 -2 -3 -4
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 601 607 628 656
Total Liabilities & Shareholder's Equity NA 718 714 722 755
Total Common Equity 0 601 607 628 656
Shares Outstanding 96.20 95.90 95.90 95.90 94.70
Book Value Per Share 0.00 6.26 6.33 6.54 6.93